Back to top
more

Universal Health Services (UHS)

(Delayed Data from NYSE)

$205.26 USD

205.26
632,500

+0.95 (0.46%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $205.49 +0.23 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 11% (28 out of 250)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.

Integer Holdings (ITGR) Gains 21.9% YTD: What's Driving the Stock?

by Zacks Equity Research

Integer Holdings (ITGR) shares gain on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.

DexCom's (DXCM) G7 CGM Coverage Expanded for Quebec Residents

by Zacks Equity Research

DexCom (DXCM) announces that Quebec residents aged two years and older living with type 1 diabetes may now be eligible to receive coverage for Dexcom G7.

The Joint (JYNT) Forays Into San Francisco Chiropractic Market

by Zacks Equity Research

This year, The Joint (JYNT) intends to open 60-70 new franchised clinics compared with 104 opened last year.

Humacyte's (HUMA) ATEV BLA Review Period Extended by FDA

by Zacks Equity Research

Humacyte's (HUMA) Biologic License Application for its ATEV faces a delay as the FDA extends its review timeline, recognizing the product's potential impact on vascular trauma treatment.

Why Universal Health Services (UHS) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Universal Health Services (UHS) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Universal Health Services (UHS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Tenet Healthcare Corporation (THC) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks

by Zacks Equity Research

Despite improving product sales, Accuray (ARAY) reports mixed fourth-quarter fiscal 2024 results.

Stereotaxis (STXS) Receives European Approval for GenesisX

by Zacks Equity Research

Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.

Solventum's (SOLV) Q2 Earnings Beat Estimates, ' 24 View Raised

by Zacks Equity Research

Solventum's (SOLV) second-quarter results show resilience in MedSurg and Health Information Systems. Its shrinking margins pose concerns.

Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sales

by Zacks Equity Research

Baxter (BAX) announces the divestiture of its Kidney Care segment, Vantive, to a global investment firm Carlyle.

Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) fourth-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.

Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are concerning.

Universal Health Services, Inc. (UHS) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Reasons to Retain Ecolab (ECL) Stock in Your Portfolio Now

by Zacks Equity Research

Ecolab's (ECL) focus on cost efficiency programs raises optimism about the stock.

Harshit Gupta headshot

Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments

by Harshit Gupta

Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions.

Stryker (SYK) to Acquire care.ai to Boost AI-Driven Healthcare

by Zacks Equity Research

Stryker's (SYK) acquisition of care.ai is set to enhance its healthcare IT offerings with AI-assisted virtual care workflows and smart room technology.

Fast-paced Momentum Stock Universal Health Services (UHS) Is Still Trading at a Bargain

by Zacks Equity Research

Universal Health Services (UHS) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge

by Zacks Equity Research

Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Accuray's (ARAY) solid product demand raises optimism about the stock.

Tracey Ryniec headshot

5 Best of the Best Stock Picks: Strong Buys and VGM of A

by Tracey Ryniec

HRB, ANF, POWL, EME and UHS have value, growth, momentum, and rising earnings estimates.

J&J's (JNJ) DePuy Synthes' TriLEAP System to Aid Ankle Surgery

by Zacks Equity Research

Johnson & Johnson's (JNJ) DePuy Synthes announces the launch of its TriLEAP System, which is likely to provide better orthopedic solutions to foot and ankle surgeons.

Bruker (BRKR) Partners With NovAliX to Boost Drug Discovery

by Zacks Equity Research

Bruker (BRKR) invests in NovAliX to accelerate advancements in drug discovery, combining cutting-edge biophysical methods and technologies to develop new treatments and enhance biopharma solutions.